A Phase Ia, Double-Blind, Single-Ascending Dose Study to Evaluate NKTR-358 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2019
Price : $35 *
At a glance
- Drugs NKTR 358 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Nektar Therapeutics
- 10 Nov 2019 Status changed from active, no longer recruiting to completed, according to a Nektar Therapeutics media release.
- 10 Nov 2019 According to a Nektar Therapeutics media release, data from this study were presented at the 2019 Annual Meeting of the American College of Rheumatology in Atlanta.
- 10 Nov 2019 Results presented in a Nektar Therapeutics media release.